Walleye Capital
XERS icon

Walleye Capital’s Xeris Biopharma Holdings XERS Stock Holding History

Walleye Capital’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.84M Buy
+611,296
New +$3.9M 0.02% 847
2025
Q4 		– Sell
-623,962
Closed -$5.08M – 5212
2025
Q3 		$5.08M Buy
623,962
+380,687
+156% +$2.53M 0.02% 917
2025
Q2 		$1.14M Sell
243,275
-448,444
-65% -$2.05M ﹤0.01% 1948
2025
Q1 		$3.8M Buy
+691,719
New +$2.79M 0.02% 964
2024
Q4 		– Sell
-1,121,738
Closed -$3.2M – 5652
2024
Q3 		$3.2M Buy
+1,121,738
New +$2.88M 0.01% 1528
2024
Q1 		– Sell
-35,927
Closed -$84.4K – 5960
2023
Q4 		$84.4K Sell
35,927
-88,763
-71% -$164K ﹤0.01% 4117
2023
Q3 		$232K Buy
+124,690
New +$286K ﹤0.01% 3437
2020
Q2 		– Sell
-113,269
Closed -$221K – 1014
2020
Q1 		$221K Buy
+113,269
New +$487K 0.05% 420

Other funds holding XERS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Walleye Capital's XERS Position: Q2 2026 in Review

Walleye Capital opened a new position in Xeris Biopharma Holdings (XERS) in Q2 2026: 611,296 shares worth $4.84M. The stake represents 0.02% of the portfolio and ranks #847 among its holdings. This is a return to the name: Walleye Capital previously reported a position in XERS as recently as Q3 2025.

Walleye Capital first reported a position in XERS in Q1 2020 and has held it in 8 quarters since. The position peaked at $5.08M in Q3 2025. 241 funds tracked by Wall St. Rank hold XERS as of Q2 2026.

  • Walleye Capital held 611,296 shares of Xeris Biopharma Holdings worth $4.84M as of Q2 2026.
  • Xeris Biopharma Holdings was a new Walleye Capital position in Q2 2026.
  • Xeris Biopharma Holdings made up 0.02% of Walleye Capital's portfolio in Q2 2026, its #847 holding.
  • Walleye Capital first reported a position in Xeris Biopharma Holdings in Q1 2020 and has held it in 8 quarters since.
  • Walleye Capital's Xeris Biopharma Holdings position peaked at $5.08M in Q3 2025.
  • 241 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.